Latest Press Coverage StablevaX™
Stablepharma and BB-NCIPD collaborating on Td vaccine
"We have established a strategic R&D partnership, alongside a statement of Intention for the future development and commercialisation of the StablevaX Td product" - Nick ChildFind out more by clicking here.
Stablepharma are delighted to have been nominated as one of the 82 Best & Fastest Growing Product Research Companies and Startups in the UK!
WHO state that c. 50% of vaccines are wasted due mostly to failures in the cold chain
Stablepharma does not manufacture vaccines, but stands ready to partner with vaccine manufacturers to add our complimentary and enhancing technology to make anti Covid-19 vaccines safe and thermostable information.
The Stablepharma team will continue to work from home and in our laboratory facilities in Europe. We have identified areas which we consider critical to operate and have developed operational continuity plans to ensure we have sufficient resources to keep our R&D work progressing.
We wish to keep our lines of communication open and those needing to contact us are able to do so. Please contact email@example.com
We wish you well during this time of uncertainty but look forward to a positive outcome for all of us.
We have invented a truly disruptive solution that can eliminate the need for refrigeration ('The Cold Chain') and eradicate vaccine wastage once approved
Receive an introduction to Stablepharma pack
Please enter your details below to receive an introduction to Stablepharma